Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension

  • Christian Jansen ,

    Contributed equally to this work with: Christian Jansen, Diana J. Leeming

    Affiliation Department of Internal Medicine I, University of Bonn, Bonn, Germany

    ⨯
  • Diana J. Leeming ,

    Contributed equally to this work with: Christian Jansen, Diana J. Leeming

    Affiliation Nordic Bioscience, Fibrosis Biology and Biomarkers, Herlev, Denmark

    ⨯
  • Mattias Mandorfer,

    Affiliation Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    ⨯
  • Inger Byrjalsen,

    Affiliation Nordic Bioscience, Fibrosis Biology and Biomarkers, Herlev, Denmark

    ⨯
  • Robert Schierwagen,

    Affiliation Department of Internal Medicine I, University of Bonn, Bonn, Germany

    ⨯
  • Philipp Schwabl,

    Affiliation Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    ⨯
  • Morten A. Karsdal,

    Affiliation Nordic Bioscience, Fibrosis Biology and Biomarkers, Herlev, Denmark

    ⨯
  • Evrim Anadol,

    Affiliation Department of Internal Medicine I, University of Bonn, Bonn, Germany

    ⨯
  • Christian P. Strassburg,

    Affiliation Department of Internal Medicine I, University of Bonn, Bonn, Germany

    ⨯
  • Jürgen Rockstroh,

    Affiliations Department of Internal Medicine I, University of Bonn, Bonn, Germany, German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany

    ⨯
  • Markus Peck-Radosavljevic,

    Affiliation Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    ⨯
  • Søren Møller,

    Affiliation Center of Functional and Diagnostic Imaging and Research, Department of Clinical Physiology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark

    ⨯
  • Flemming Bendtsen,

    Affiliation Gastro Unit, Medical Division, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

    ⨯
  • Aleksander Krag,

    Affiliation Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark

    ⨯
  • Thomas Reiberger ,

    These authors also contributed equally to this work

    Affiliation Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    ⨯
  •  [ ... ],
  • Jonel Trebicka

    jonel.trebicka@ukb.uni-bonn.de

    These authors also contributed equally to this work

    Affiliation Department of Internal Medicine I, University of Bonn, Bonn, Germany

    ⨯
  • [ view all ]
  • [ view less ]

Abstract

Background

Liver-related deaths represent the leading cause of mortality among patients with HIV/HCV-co-infection, and are mainly related to complications of fibrosis and portal hypertension. In this study, we aimed to evaluate the structural changes by the assessment of extracellular matrix (ECM) derived degradation fragments in peripheral blood as biomarkers for fibrosis and portal hypertension in patients with HIV/HCV co-infection.

Methods

Fifty-eight patients (67% male, mean age: 36.5 years) with HIV/HCV-co-infection were included in the study. Hepatic venous pressure gradient (HVPG) was measured in forty-three patients. The fibrosis stage was determined using FIB4 -Score. ECM degraded products in peripheral blood were measured using specific ELISAs (C4M, MMP-2/9 degraded type IV collagen; C5M, MMP-2/9 degraded type V collagen; PRO-C3, MMP degraded n-terminal propeptide of type III collagen).

Results

As expected, HVPG showed strong and significant correlations with FIB4-index (rs = 0.628; p = 7*10−7). Interestingly, PRO-C3 significantly correlated with HVPG (rs = 0.354; p = 0.02), alanine aminotransferase (rs = 0.30; p = 0.038), as well as with FIB4-index (rs = 0.3230; p = 0.035). C4M and C5M levels were higher in patients with portal hypertension (HVPG>5 mmHg).

Conclusion

PRO-C3 levels reflect liver injury, stage of liver fibrosis and degree of portal hypertension in HIV/HCV-co-infected patients. Furthermore, C4M and C5M were associated with increased portal pressure. Circulating markers of hepatic ECM remodeling might be helpful in the diagnosis and management of liver disease and portal hypertension in patients with HIV/HCV coinfection.

Citation: Jansen C, Leeming DJ, Mandorfer M, Byrjalsen I, Schierwagen R, Schwabl P, et al. (2014) PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. PLoS ONE 9(9): e108544. https://doi.org/10.1371/journal.pone.0108544

Editor: Matias A. Avila, University of Navarra School of Medicine and Center for Applied Medical Research (CIMA), Spain

Received: July 9, 2014; Accepted: August 22, 2014; Published: September 29, 2014

Copyright: © 2014 Jansen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by: 1. Deutsche Forschungsgemeinschaft (SFB TRR57 P18 to Jonel Trebicka); 2. J. & W. Hector-Foundation (to Jonel Trebicka); 3. unrestricted research grants from Roche Austria (to Markus Peck-Radosavljevic); 4. MSD Austria (to Markus Peck-Radosavljevic); 5. DZIF TTU HIV Project 05.803; 6. German Center for Infection Research (DZIF); 7. Danish Science Foundation; and 8. Danish Ministry of Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: Diana J. Leeming, Morten A. Karsdal, and Inger Byrjalsen are employees of Nordic Bioscience, a company engaged in the development of biochemical markers. Morten A. Karsdal is a stockholder of Nordic Bioscience. The other authors have no conflict of interest. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Introduction

Combined antiretroviral treatment (cART) is able to control the HIV replication in the majority of HIV patients, and thereby reduce mortality [1], [2]. While a decrease of AIDS-related deaths are noted, mortality related to chronic liver diseases is steadily increasing in HIV patients [3]–[5]. Nearly 24% of non-AIDS related deaths in HIV-infected patients are due to end-stage liver disease (ESLD), with 66% being attributed to HCV co-infection and 17% to HBV co-infection [5]. This represents an important socioeconomic problem, given the fact that more than 30% of HIV-patients in Europe and USA are co-infected [4]. HCV replication is increased in HIV coinfection [6], whereas HCV-specific immune responses are attenuated [7]–[10], which may be the cousal factors to the progression of liver fibrosis and accelerated development of ESLD in patients with HCV/HIV co-infection as compared to HCV mono-infected patients [11], [12]. ESLD is associated with complications and mortality mainly due to portal hypertension. Measurement of hepatic venous pressure gradient (HVPG) is the best available tool to directly assess portal hypertension[13]–[16]. Thus, the early detection of fibrosis and portal hypertension especially in HIV/HCV co-infected patients represents an unmet clinical need.

During progression of liver fibrosis both, the synthesis and degradation of extracellular matrix (ECM) are increased – referred to as ECM remodeling [17]–[19]. Endopeptidases, such as matrix metalloproteinases (MMPs) MMP-2 and MMP-9 are enhanced during ECM remodeling, especially in HIV-positive patients [20]–[22]. During the synthesis and degradation of collagen by MMPs small fragments are released into the circulation, and their levels mirror the extent of liver dysfunction and portal hypertension in patients with alcoholic cirrhosis [17].

The aims of the present study were to evaluate circulating collagen fragments as biomarkers for (i) liver fibrosis stage and (ii) portal hypertension in patients with HIV/HCV coinfection.

Materials and Methods

Study design

We retrospectively included fifty-eight (67% male) patients with HIV/HCV coinfection. The median age was 36.5 years (range 19 to 63). HVPG was measured in forty-three patients. The fibrosis stage was determined using Fibroscan and FIB4-Score (Table 1). Circulating collagen fragments in peripheral serum were measured in all patients during routine blood sampling as previously described (Table S1). Furthermore, biochemical parameters were analyzed using standard methods (Table 2). The patients gave their written consent for the procedures and the local ethics committee of the University of Bonn (Nr. 069/10) as well as the local ethics committee of the University of Vienna (EK 005/2005) approved the study [23] in accordance with the Declaration of Helsinki.

thumbnail
Download:
Table 1. Clinical parameters of patients.

https://doi.org/10.1371/journal.pone.0108544.t001

thumbnail
Download:
Table 2. Biochemical parameters of included patients.

https://doi.org/10.1371/journal.pone.0108544.t002

Measurement of HVPG, liver stiffness by transient elastography and calculation of FIB-4 Index

HVPG measurements were performed as previously described [13], [24], [25]. Under local anesthesia and ultrasound guidance, the right internal jugular was canulated by usage of the Seldinger technique. A balloon catheter was placed under continuous radiological control in a major hepatic vein. To calculate HVPG, three repeated measurements of free and wedged hepatic venous pressure were performed. Pressure curves were continuously recorded using a licensed software (S5 Collect, Vienna, Austria).

Transient elastography (Fibroscan, Echosens, France) was used for measurement liver stiffness as previously described [25]–[27].

FIB4-index was calculated in 43 patients, as previously described [28]. FIB4-index is based on AST, ALT, platelet count, and age: FIB4 = (age [years] × AST [IU L−1])/(platelet count [109 L−1]×√ALT [IU L−1]).

Enzyme-linked immunosorbentassay

Specific enzyme-linked immunosorbentassay (ELISA) were assessed in the described patient group following a protocol as previously described [17] to detect degradation of ECM fragments. In detail: PRO-C3 (true collagen type III formation) [29] C4M (MMP-2/9 degraded type IV collagen) [30] and C5M (MMP-2/9 degraded type V collagen) [31] were quantified (Table S1).

Statistical analysis

Mann-Whitney-U test was used for unpaired comparisons. The correlations were analyzed by the use of Spearman correlation coefficient. Significant differences in levels of circulating biomarkers in peripheral blood between more than two groups were analyzed using Kruskal-Wallis-Test. p<0.05 was considered as statistically significant. Statistical analyses were performed with SPSS 22 (SPSS Inc. Chicago, IL, USA).

Results

Clinical, biochemical, and haemodynamic characteristics of patients

The clinical characteristics of the study population are shown in Table 1. The biochemical parameters including the levels of ECM markers are shown in Table 2. All patients were treated with cART and HIV viral load was under detection level.

FIB-4 index was calculated in forty-three patients as previously described [28]. Seven patients showed no or F1 fibrosis, 30 patients showed stage F2 or F3 and six patients showed fibrosis F4 (Table 1; Figure 1C). Using transient elastography with a median of 7 kPa (range 3–22 kPa), more patients showed a mild fibrosis (F0/1 n = 23; F2/3 n = 18; F4 n = 5) (Table 1). HVPG was measured in forty-three patients. The median pressure was 3 mmHg (range: 2–13 mmHg). HVPG correlated with FIB-4 index (rs = 0.628; p = 7*10−7), liver stiffness (rs = 0.621; p = 9*10−5), and inversely with platelet counts (rs = −0.366; p = 0.016) (Figure S1). The strong correlation of HVPG with liver stiffness serves as internal quality control of the data raised in the patients.

thumbnail
Download:
Figure 1. Levels of PRO-C3 measured in blood of patients with HIV/HCV co-infection correlated with hemodynamic and liver function parameters as well with FIB4-Score.

The levels of PRO-C3 (A) correlated with HVPG (rs = 0.354; p = 0.02) as well as the levels of ALT (rs = 0.3; p = 0.038) (B). Furthermore significant higher levels of PRO-C3 could be observed in patients with advanced fibrosis stratified using FIB4-Score (p = 0.006) (C). Instead using fibroscan to stratify patient in the same way only a tendency could be seen (p = 0.094) (D).

https://doi.org/10.1371/journal.pone.0108544.g001

Relationship between PRO-C3 levels and parameters of liver injury

Interestingly, serum PRO-C3 levels significantly correlated with HVPG (rs = 0.354; p = 0.020; Figure-1A; Table 3). Furthermore, PRO-C3 levels significantly correlated with ALT as a marker of liver injury (rs = 0.30; p = 0.038; Figure 1B; Table 3).

thumbnail
Download:
Table 3. Correlations of PRO-C3 with fibrosis, portal hypertension and liver function.

https://doi.org/10.1371/journal.pone.0108544.t003

Moreover, serum PRO-C3 correlated with FIB-4 index (rs = 0.323; p = 0.035; Table 3) and was significantly higher in patients with advanced fibrosis as indicated either by FIB-4 index or transient elastography (Figure 1C, 1D).

Relationship between serum C4M and C5M levels and parameters of liver injury

Levels of serum C5M significantly correlated with FIB-4 index (rs = 0.314; p = 0.04; Figure 2B) and were higher in patients with portal hypertension defined as HVPG above 5 mmHg (Figure 2C). Interestingly, serum levels of C4M were significant higher (p = 0.014) in patients with portal hypertension (Figure 2A).

thumbnail
Download:
Figure 2. FIB4 score correlated significant with C5M (B).

Serum levels of C5M (C) and C4M (A) stratified between patients with higher and lower or equal hepatic venous pressure gradient than 5 mmHg differ. Levels of serum C5M (B) correlated significantly with FIB4-score (rs = 0.314; p = 0.04). Stratified patients between higher and lower hepatic venous pressure gradient than 5 mmHg showed significant differ in levels of serum C4M (p = 0.014) (A). Levels of C5M (p = 0.061) (C) only showed a tendency. Data are shown by using box-plots and were analyzed with the Wilcoxon test.

https://doi.org/10.1371/journal.pone.0108544.g002

Discussion

This study demonstrated that serum PRO-C3 levels may serve as biomarkers for the extent of liver fibrosis, liver injury, and portal hypertension in HIV/HCV-co-infected patients. Additional markers of ECM remodeling such as serum C4M and C5M levels might be useful in these patients to non-invasively diagnose the presence of portal hypertension.

ECM remodelling occurs as an attempt to repair damaged tissue response to liver injury [14], [32]–[34], while ongoing hepatic injury leads to a non-regenerative wound healing characterized by high turnover of ECM and ultimately, a net accumulation of fibrotic scar tissue in the liver. The deposition of fibrotic material continuously increases intrahepatic vascular resistance to portal blood flow and thereby causing portal hypertension [35], [36]. Therefore, the progression of fibrosis and development of portal hypertension are closely associated [37]. Especially in patients with HIV/HCV co-infection the evaluation of fibrosis and portal hypertension represents a major issue, since disease progression is accelerated [38] and liver-related mortality is increasing [3]–[5]. These patients might be asymptomatic until clinical decompensation occurs, but at this stage preventing morbidity and mortality represents a major clinical challenge. Therefore, non-invasive biomarkers are needed for early detection of liver fibrosis and portal hypertension - before clinically significant complications and decompensation occur.

The present study showed that the collagen type III formation marker PRO-C3 correlated with liver injury, fibrosis, and portal hypertension in HIV/HCV co-infected patients. This marker was previously described to derive from the diseased liver and reflects fibrosis and portal hypertension in animal models of fibrosis [18] and in humans with alcoholic cirrhosis [17]. The PRO-C3 ELISA is different and may be superior to other commercial available assays since other commercial PIIINP assays available utilize either a monoclonal- or polyclonal antibody, from which the precise epitope is not known. The Pro-C3 ELISA utilized a monoclonal antibody specific for the PIIINP cleavage site resulting in a stronger surrogate for collagen III formation. This has been described in Nielsen et al. [29]. In the present work we confirmed that PRO-C3 reflects ECM remodelling and liver fibrogenesis in HIV/HCV coinfected patients. Most importantly, PRO-C3 seems to be a valuable biomarker for liver fibrosis stage and portal hypertension in HIV/HCV coinfection.

Furthermore, systemically assessed type IV (C4M) and V collagen (C5M) fragments were significantly higher in HIV/HCV-co-infected patients with portal hypertension. Interestingly, the level of C4M and C5M reflects not only the release of ECM-fragments, but also the turnover of ECM [18], and thereby may mirror the extent and activity of fibrotic processes. In contrast to PRO-C3, C4M is a marker of basement membrane degradation [30]. But similarly to the formation marker PRO-C3, C4M levels were also shown to be elevated in BDL and CCl4-treated rats [18]. In addition, we showed recently that C4M together with PRO-C3 has the highest diagnostic power as single marker to identify clinically relevant HVPG in patients with alcoholic cirrhosis [17]. Thus the present data are in alignment. Moreover, in a rat model of liver fibrosis C4M was correlated with the effect of antifibrotic treatment, which has still not deep validated in human studies [18]. All these studies have demonstrated that collagen degradation occurs in fibrotic processes and is may act as a mirror of the synthesis of collagen at a similar extent as the synthesis of collagen. Once again this study reinforces the strong causal association between ECM remodeling and portal hypertension. The present study confirms the importance of PRO-C3 and C4M as predictor of portal hypertension also in patients with HIV/HCV coinfection.

Interestingly, this study underlines a potential role of collagen type V degradation marker in the HIV/HCV patients. Fibrosis of lymphoid tissue has been described as a milestone of disease progression in HIV, and besides spleen, gut and lymph nodes, the liver is a major organ involved in the immune response towards pathogens [39]. In the presence of additional HCV infection, the liver disease may be the major couse of morbidity and mortality and this study is the first to highlight the potential pathogenetic role of collagen type V degradation in the progression of fibrosis and development of portal hypertension. Thus, our previous results in patients with alcoholic cirrhosis [18] also apply in patients with HIV/HCV-co-infection. As previously described type V collagen is a key player in formation and assembly of other collagens. Therefore it is not surprising that also increased levels of C5M has been described in diseases with abnormally high collagen remodeling such as chronic obstructive pulmonary disease [40] and idiopathic pulmonary fibrosis [40] and ankylosing spondylitis [31].

Limitations

Although these patients were well characterized the present study has several limitations. We examined in this study a very selective small group of patients, which might be a bias of the study. Besides that, the validity of the results is strengthened, since they are well in line with previously published findings of correlation of HVPG with FIB-4 score, transient elastography assessed by Fibroscan, platelet count and aminotransferases levels [41]–[44]. Therefore, our identified markers may serve as early marker of liver injury, fibrosis and portal hypertension.

In conclusion, this study demonstrates that liver fibrosis and liver injury might be reflected by PRO-C3-levels in HIV/HCV-co-infected patients. PRO-C3 correlated with HVPG and parameters of hepatic dysfunction. Furthermore higher levels of C4M and C5M were associated with degree of portal hypertension.

Supporting Information

Figure S1.

Correlation of HVPG with FIB4-Score (A), fibroscan (B) and PLT (C). HVPG correlates with FIB4-Score (rs = 0.628; p = 7*10−7) (A) as well with fibrosacan (rs = 0.621; p = 9*10−5) (B) and inversely with PLT (rs = −0.366; p = 0.016) (C). Data are presented using Spearman coefficient rs and p-values.

https://doi.org/10.1371/journal.pone.0108544.s001

(TIFF)

Table S1.

Overview of technical specification of the novel ECM assays presented in this study.

https://doi.org/10.1371/journal.pone.0108544.s002

(DOC)

Acknowledgments

We thank Gudrun Hack, Lise Larsen and Silke Bellinghausen for their excellent technical assistance.

Author Contributions

Conceived and designed the experiments: DJL MAK TR JT. Performed the experiments: CJ MM RS PS EA. Analyzed the data: CJ IB DJL TR JT. Contributed reagents/materials/analysis tools: DJL MAK CPS JR MPR SM FB AK TR JT. Contributed to the writing of the manuscript: CJ DJL MAK MM RS PS EA CPS JR MPR SM FB AK TR JT.

References

  1. 1. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL (2001) Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA 285: 1308–1315.
  2. 2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22–29.
  3. 3. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, et al. (2005) Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 19: 2117–2125.
  4. 4. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, et al. (2007) Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 14: 183–188.
  5. 5. Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K (2011) Increasing burden of liver disease in patients with HIV infection. Lancet 377: 1198–1209.
  6. 6. Deng A, Chen C, Ishizaka Y, Chen X, Sun B, et al. (2014) Human immunodeficiency virus type 1 Vpr increases hepatitis C virus RNA replication in cell culture. Virus Res 184C: 93–102.
  7. 7. Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, et al. (2010) HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 40: 2493–2505.
  8. 8. Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946–952.
  9. 9. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, et al. (1999) Analysis of a successful immune response against hepatitis C virus. Immunity 10: 439–449.
  10. 10. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, et al. (1999) Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 117: 933–941.
  11. 11. Rotman Y, Liang TJ (2009) Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 83: 7366–7374.
  12. 12. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, et al. (2005) HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41: 779–789.
  13. 13. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC (2009) The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 6: 573–582.
  14. 14. Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet.
  15. 15. Garcia-Pagan JC, Di Pascoli M, Caca K, Laleman W, Bureau C, et al. (2013) Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 58: 45–50.
  16. 16. Garcia-Pagan JC, Reverter E, Abraldes JG, Bosch J (2012) Acute variceal bleeding. Semin Respir Crit Care Med 33: 46–54.
  17. 17. Leeming DJ, Karsdal MA, Byrjalsen I, Bendtsen F, Trebicka J, et al. (2013) Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 38: 1086–1096.
  18. 18. Schierwagen R, Leeming DJ, Klein S, Granzow M, Nielsen MJ, et al. (2013) Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Front Physiol 4: 195.
  19. 19. Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, et al. (2011) A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16: 616–628.
  20. 20. Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, et al. (2013) Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 11: 70–92.
  21. 21. Larrousse M, Laguno M, Segarra M, De Lazzari E, Martinez E, et al. (2007) Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 46: 304–311.
  22. 22. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, et al. (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223–2233.
  23. 23. Reiberger T, Payer BA, Ferlitsch A, Sieghart W, Breitenecker F, et al. (2012) A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 17: 1327–1334.
  24. 24. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, et al. (2011) Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 9: 602–608 e601.
  25. 25. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, et al. (2013) Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62: 1634–1641.
  26. 26. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Schwabl P, et al. (2012) Noninvasive screening for liver fibrosis and portal hypertension by transient elastography–a large single center experience. Wien Klin Wochenschr 124: 395–402.
  27. 27. Schwabl P, Bota S, Salzl P, Mandorfer M, Payer B, et al. (2014) New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int.
  28. 28. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, et al. (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46: 32–36.
  29. 29. Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, et al. (2013) The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 5: 303–315.
  30. 30. Veidal SS, Karsdal MA, Nawrocki A, Larsen MR, Dai Y, et al. (2011) Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 4: 22.
  31. 31. Veidal SS, Larsen DV, Chen X, Sun S, Zheng Q, et al. (2012) MMP mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin Biochem 45: 541–546.
  32. 32. Liedtke C, Luedde T, Sauerbruch T, Scholten D, Streetz K, et al. (2013) Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 6: 19.
  33. 33. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, et al. (2013) Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 58: 234–239.
  34. 34. Buck M, Garcia-Tsao G, Groszmann RJ, Stalling C, Grace ND, et al. (2014) Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology 59: 1052–1059.
  35. 35. Bosch J, Garcia-Tsao G (2009) Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: and the winner is. Hepatology 50: 674–677.
  36. 36. Bosch J (2000) Prevention of variceal rebleeding: endoscopes, drugs, and more. Hepatology 32: 660–662.
  37. 37. Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, et al. (2014) Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int.
  38. 38. Alesiani M, Pellegrini Giampietro DE, Cherici G, Galli A, Moroni F (1990) The guinea pig myenteric plexus as a tool to characterize drugs active at the glycine recognition site of the NMDA receptors. Pharmacol Res 22 Suppl 1: 15–16.
  39. 39. Estes JD (2013) Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol Rev 254: 65–77.
  40. 40. Leeming DJ, Sand JM, Nielsen MJ, Genovese F, Martinez FJ, et al. (2012) Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark Insights 7: 119–126.
  41. 41. Sanchez-Conde M, Miralles P, Bellon JM, Rincon D, Ramirez M, et al. (2011) Use of transient elastography (FibroScan(R)) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat 18: 685–691.
  42. 42. Liu W, Zheng J, Xing R (2014) Clinical significance of a scoring formula of liver injury for the preoperative evaluation of patients with liver cirrhosis. Eur J Gastroenterol Hepatol 26: 95–100.
  43. 43. van Beek JH, de Moor MH, de Geus EJ, Lubke GH, Vink JM, et al. (2013) The genetic architecture of liver enzyme levels: GGT, ALT and AST. Behav Genet 43: 329–339.
  44. 44. M’Kada H, Munteanu M, Perazzo H, Ngo Y, Ramanujam N, et al. (2011) What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regul Toxicol Pharmacol 60: 290–295.